A citation-based method for searching scientific literature

Rebecca Arend, Shannon Neville Westin, Robert L Coleman. Int J Gynecol Cancer 2020
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The forefront of ovarian cancer therapy: update on PARP inhibitors.
M R Mirza, R L Coleman, A González-Martín, K N Moore, N Colombo, I Ray-Coquard, S Pignata. Ann Oncol 2020
43
100

CD95 promotes tumour growth.
Lina Chen, Sun-Mi Park, Alexei V Tumanov, Annika Hau, Kenjiro Sawada, Christine Feig, Jerrold R Turner, Yang-Xin Fu, Iris L Romero, Ernst Lengyel,[...]. Nature 2010
262
50

The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
Yangjiong Xiao, Yang Yu, Pengcheng Jiang, Yuhong Li, Chao Wang, Rong Zhang. Cell Oncol (Dordr) 2020
6
50

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
50

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
957
50

Pathogenesis and heterogeneity of ovarian cancer.
Paul T Kroeger, Ronny Drapkin. Curr Opin Obstet Gynecol 2017
99
50

Pancreatic progenitor cell differentiation and proliferation factor predicts poor prognosis in heptaocellular carcinoma.
Zhengfa Mao, Xi Li, Xiaoyan Ma, Xuqing Wang, Jiangxin Zhang, Xin Fan. Medicine (Baltimore) 2019
5
50

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future.
Nicoletta Colombo, Domenica Lorusso, Paolo Scollo. Int J Gynecol Cancer 2017
24
50

The heterogeneity of ovarian cancer.
I Meinhold-Heerlein, S Hauptmann. Arch Gynecol Obstet 2014
50
50

Circular RNA circ-FOXM1 facilitates cell progression as ceRNA to target PPDPF and MACC1 by sponging miR-1304-5p in non-small cell lung cancer.
Guohua Liu, Hanbing Shi, Liling Deng, Hongyan Zheng, Weili Kong, Xiaoqiang Wen, Hongxia Bi. Biochem Biophys Res Commun 2019
40
50

Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers.  2017
446
50

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Ahmed Ashour Ahmed, Dariush Etemadmoghadam, Jillian Temple, Andy G Lynch, Mohamed Riad, Raghwa Sharma, Colin Stewart, Sian Fereday, Carlos Caldas, Anna Defazio,[...]. J Pathol 2010
439
50

Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
S Balendran, S Liebmann-Reindl, A S Berghoff, T Reischer, N Popitsch, C B Geier, L Kenner, P Birner, B Streubel, M Preusser. J Neurooncol 2017
16
50

Platinum Resistance in Ovarian Cancer: Role of DNA Repair.
Giovanna Damia, Massimo Broggini. Cancers (Basel) 2019
97
50

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
850
50

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Weiva Sieh, Martin Köbel, Teri A Longacre, David D Bowtell, Anna deFazio, Marc T Goodman, Estrid Høgdall, Suha Deen, Nicolas Wentzensen, Kirsten B Moysich,[...]. Lancet Oncol 2013
228
50

The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk. Gynecol Oncol Res Pract 2016
84
50

Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.
Yangjiong Xiao, Yang Yu, Dan Gao, Wangrui Jin, Pengcheng Jiang, Yuhong Li, Chao Wang, Yuning Song, Peng Zhan, Fei Gu,[...]. Front Oncol 2019
6
50

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
Stergios Boussios, Michele Moschetta, Peeter Karihtala, Eleftherios P Samartzis, Matin Sheriff, George Pappas-Gogos, Mehmet Akif Ozturk, Mario Uccello, Afroditi Karathanasi, Michail Tringos,[...]. Ann Transl Med 2020
5
50

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
50


Mucinous epithelial ovarian carcinoma.
T J Perren. Ann Oncol 2016
53
50

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
Martin Köbel, Steve E Kalloger, Niki Boyd, Steven McKinney, Erika Mehl, Chana Palmer, Samuel Leung, Nathan J Bowen, Diana N Ionescu, Ashish Rajput,[...]. PLoS Med 2008
555
50

Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.
Mark A Eckert, Fabian Coscia, Agnieszka Chryplewicz, Jae Won Chang, Kyle M Hernandez, Shawn Pan, Samantha M Tienda, Dominik A Nahotko, Gang Li, Ivana Blaženović,[...]. Nature 2019
113
50

Latest clinical evidence of maintenance therapy in ovarian cancer.
Christine S Walsh. Curr Opin Obstet Gynecol 2020
12
50


Models of ovarian cancer metastasis: Murine models.
Sanja Sale, Sandra Orsulic. Drug Discov Today Dis Models 2006
21
50

Driving Immune Responses in the Ovarian Tumor Microenvironment.
Franklin Ning, Christopher B Cole, Christina M Annunziata. Front Oncol 2021
4
50

Exdpf is a key regulator of exocrine pancreas development controlled by retinoic acid and ptf1a in zebrafish.
Zhi Jiang, Jianbo Song, Fei Qi, An Xiao, Xizhou An, Ning-ai Liu, Zuoyang Zhu, Bo Zhang, Shuo Lin. PLoS Biol 2008
23
50


Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
705
50

Ovarian cancer: strategies for overcoming resistance to chemotherapy.
Roshan Agarwal, Stan B Kaye. Nat Rev Cancer 2003
809
50


Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer.
Hiroyuki Yoshida, Wenjun Cheng, Jamie Hung, Denise Montell, Erika Geisbrecht, Daniel Rosen, Jinsong Liu, Honami Naora. Proc Natl Acad Sci U S A 2004
101
50

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
50



Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
50

BRCA1 and Its Network of Interacting Partners.
Charita M Christou, Kyriacos Kyriacou. Biology (Basel) 2013
24
50

PALB2/FANCN: recombining cancer and Fanconi anemia.
Marc Tischkowitz, Bing Xia. Cancer Res 2010
122
50

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira,[...]. N Engl J Med 2014
480
50

Mechanisms of PARP inhibitor sensitivity and resistance.
Alan D D'Andrea. DNA Repair (Amst) 2018
136
50

Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.
Katharina Schlacher, Nicole Christ, Nicolas Siaud, Akinori Egashira, Hong Wu, Maria Jasin. Cell 2011
701
50

TP53 Mutations in Breast and Ovarian Cancer.
Laxmi Silwal-Pandit, Anita Langerød, Anne-Lise Børresen-Dale. Cold Spring Harb Perspect Med 2017
46
50

Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Rohit Prakash, Yu Zhang, Weiran Feng, Maria Jasin. Cold Spring Harb Perspect Biol 2015
360
50


Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.
J M Piek, P J van Diest, R P Zweemer, J W Jansen, R J Poort-Keesom, F H Menko, J J Gille, A P Jongsma, G Pals, P Kenemans,[...]. J Pathol 2001
469
50

BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
Yaning Zhu, Jian Wu, Chengwan Zhang, Suan Sun, Jian Zhang, Wenjie Liu, Jian Huang, Zhihong Zhang. Oncotarget 2016
24
50

BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
Ielizaveta Gorodetska, Iryna Kozeretska, Anna Dubrovska. J Cancer 2019
47
50



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.